ArticleInternational journal of rheumatic diseases2026
JAK Inhibitor Tofacitinib Ameliorates Inflammation Response and Osteogenic Differentiation in Immune-Mediated Inflammatory Arthritis in Rats.
Article in International journal of rheumatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThis study sought to investigate the mechanism by which tofacitinib affects inflammatory response and osteogenic differentiation in immune-mediated inflammatory arthritis in rats in relation to Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3).
methodsWistar male rats were induced by the combination of bovine proteoglycan and incomplete/complete Freund's adjuvant to establish the immune-mediated inflammatory arthritis model. The clinical manifestations were observed. Hematoxylin and eosin staining was used to evaluate pathological changes in sacroiliac joints and surrounding cartilage. Additionally, the levels of osteogenic differentiation-related proteins, serum inflammatory factors, and alkaline phosphatase (ALP) were measured. Flow cytometry was conducted to analyze the proportion of Th17 cells in peripheral blood. Alizarin red staining detected the osteogenic differentiation of ligament fibroblasts.
resultsThe rats exhibited joint swelling, inflammatory infiltration in the sacroiliac joint, and cartilage destruction after modeling. Elevations were also detected in the levels of serum pro-inflammatory factors, the proportion of Th17 cells, ALP activity, phosphorylated (p)-JAK1/2, p-STAT3, osteogenic differentiation markers in ligament fibroblasts, as well as in the mineralized nodules. Tofacitinib intervention inhibited the phosphorylation of JAK and STAT3, downregulated bone differentiation-related proteins, decreased the mineralized nodules, reduced the activity of ALP, and decreased the levels of pro-inflammatory factors. However, the combined use of the STAT3 agonist Colivelin partially reversed the inhibitory effect of tofacitinib on joint inflammation and osteogenic differentiation.
conclusionTofacitinib alleviated the inflammatory response in immune-mediated inflammatory arthritis and inhibited osteogenic differentiation in rats via inhibition of the JAK/STAT3 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.